Outcomes 15 years after valve replacement with a mechanical versus a bioprosthetic valve: final report of the Veterans Affairs randomized trial.

By K. Hammermeister, G. Sethi, W. Henderson, F. Grover, C. Oprian, S. Rahimtoola. Journal of the American College of Cardiology, 2000

1,137 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Epidemiology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/6c543aac3c203e4ddf761e660293c55044d2b3cc

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Catherine M. Otto
2. Rick A. Nishimura
3. R. Bonow
4. P. O'Gara
5. Thoralf M. Sundt
6. John Erwin
7. Annemarie Thompson
8. M. Mack

In Epidemiology

1. Rick A. Nishimura
2. Catherine M. Otto
3. P. O'Gara
4. R. Bonow
5. John Erwin
6. Thoralf M. Sundt
7. Annemarie Thompson
8. M. Mack

Citations in the corpus

• A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. (2003, background): “The age threshold for choosing a bioprosthesis or a mechanical prosthesis remains a matter of debate.(28) In the current guidelines the threshold for choosing a mechanical valve over a bioprosthesis is 65.”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “Patients <50 years of age at the time of valve implantation i ncur a higher and earlier risk of bioprosthetic valve deterioration (141,149,151,155-157).”
• Calcification of tissue heart valve substitutes: progress toward understanding and prevention. (2005, background): “Within 10 years postoperatively, prosthesis-associated problems overall necessitate reoperation or cause death in at least 50% to 60% of patients with substitute valves [3, 4].”
• Guidelines on the management of valvular heart disease (version 2012): the Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). (2012, neutral): “Long-term survival was very similar.(199,200) A more recent trial randomized 310 patients aged 55–70 years to mechanical or biological prostheses.”
• 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. (2017, background): “Patients <50 years of age at the time of valve implantation i ncur a higher and earlier risk of bioprosthetic valve deterioration (141,149,151,155-157).”
• Guidelines on the management of valvular heart disease The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (2006, neutral): “Long-term survival was very similar [199, 200].”
• Engineering Complex Tissues (2006, positive): “Although valve surgery generally leads to enhanced survival and quality of life, presently available valve substitutes provide imperfect functional restitution and have potential complications.(136,137) Moreover, in pediatric applications, where although physiologically corrective procedures can be ”
• 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “TTE is indicated for baseline evaluation of LV size and function, right ventricular (RV) function and left atrial size, pulmonary artery pressure, and mechanism and severity of primary MR (stages A to D) in any patient suspected of having chronic primary MR (6, 23, 146-162).”